<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00248365</url>
  </required_header>
  <id_info>
    <org_study_id>CR-ECP-001</org_study_id>
    <nct_id>NCT00248365</nct_id>
  </id_info>
  <brief_title>Theralux Extracorporeal Photochemotherapy (ECP) in Patients With Extensive Chronic Graft Versus Host Disease (GvHD)</brief_title>
  <official_title>Safety, Biological and Clinical Efficacy of Two Intensity Levels of Theralux Extracorporeal Photochemotherapy in Subjects With Extensive Chronic GvHD Refractory or Intolerant to Standard Therapy: A Randomized, Open-label Phase I/II Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kiadis Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kiadis Pharma</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the tolerability and safety of two intensity levels of&#xD;
      Theralux extracorporeal photochemotherapy in the treatment of subjects with steroid&#xD;
      refractory or intolerant GvHD.&#xD;
&#xD;
      The current hypothesis is that apoptotic cells re-injected into patients induce an&#xD;
      immunomodulation effect alleviating the GvHD symptoms. Using the Theralux procedure, the dose&#xD;
      of photodynamic treatment may be modulated to achieve the maximal immunomodulatory effects in&#xD;
      the treated patients.&#xD;
&#xD;
      The intervention is iterative extracorporeal photochemotherapy of autologous peripheral blood&#xD;
      mononuclear cells (PBMC) with a rhodamine-derivative TH9402 (drug) and Theralux (device).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Graft versus host disease (GvHD) remains a major cause of morbidity and mortality related to&#xD;
      allogeneic stem cell transplantation. While improvements in immuno-suppressive regimens have&#xD;
      reduced the frequency and severity of acute GvHD, the incidence of chronic GvHD (cGvHD)&#xD;
      remains unchanged ranging from 30% after sibling matched related donor transplants to over&#xD;
      70% after unrelated donor bone marrow or peripheral blood stem cell transplant. Factors&#xD;
      associated with cGvHD include increased donor and recipient age, prior acute GvHD, and the&#xD;
      use of alloimmune female donors. Conventional therapeutic approaches for cGvHD, including&#xD;
      corticosteroids and immunosuppressive agents, have demonstrated limited efficacy in patients&#xD;
      with extensive disease and are associated with high toxicity.&#xD;
&#xD;
      Iterative extracorporeal photopheresis has demonstrated clinical and immunomodulatory&#xD;
      activity in subjects with acute and chronic GvHD. The currently available process of ECP has&#xD;
      not been controlled for cell number, exposure time, or specific cell populations targeted due&#xD;
      to the nature of the procedure. Using the Theralux procedure, defined populations of cells&#xD;
      may be targeted, and the intensity of photoactivating agent and exposure can be modulated to&#xD;
      achieve the maximal immunomodulatory effects in the treated subjects. This study will attempt&#xD;
      to explore the effects of the Theralux procedure under two defined conditions. Response and&#xD;
      toxicity will be determined at each intensity level and the dose associated with clinical&#xD;
      response and immunomodulatory effects on DC and NK cell populations will be defined as the&#xD;
      optimal intensity level for subsequent larger trials.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Signs of toxicity</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Chronic GvHD grading</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose of immunosuppressive medications</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>ECOG Performance</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunomodulatory and Biological effects</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Graft vs Host Disease</condition>
  <arm_group>
    <arm_group_label>Low PDT intensity level</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Theralux extracorporeal photochemotherapy PDT dose: TH9402 0.33μM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High PDT intensity level</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Theralux extracorporeal photochemotherapy PDT dose: TH9402 1.32μM</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Theralux extracorporeal photochemotherapy</intervention_name>
    <arm_group_label>High PDT intensity level</arm_group_label>
    <arm_group_label>Low PDT intensity level</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical features compatible with extensive chronic GvHD&#xD;
&#xD;
          -  Refractory or intolerant to standard therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Underlying concurrent medical condition which would hinder the ability to safely&#xD;
             administer the treatment&#xD;
&#xD;
          -  Known hepatitis B virus (HBV) or hepatitis C virus (HCV) infection&#xD;
&#xD;
          -  Participation to another investigational trial within 30 days of study entry&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>B.C. Cancer Research Center</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1L3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McMaster University Medical Center</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa General Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maisonneuve-Rosemont Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.kiadispharma.com</url>
    <description>Kiadis Pharma Web page</description>
  </link>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>November 3, 2005</study_first_submitted>
  <study_first_submitted_qc>November 3, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2005</study_first_posted>
  <last_update_submitted>February 24, 2016</last_update_submitted>
  <last_update_submitted_qc>February 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2016</last_update_posted>
  <keyword>Chronic GvHD</keyword>
  <keyword>Extensive chronic GvHD</keyword>
  <keyword>Resistant chronic GvHD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

